Cognition Therapeutics In... (CGTX)
NASDAQ: CGTX
· Real-Time Price · USD
1.46
-0.03 (-2.01%)
At close: Aug 19, 2025, 11:46 AM
-2.01% (1D)
| Bid | 1.45 |
| Market Cap | 107.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.3M |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | -2.21 |
| Forward PE | -2.7 |
| Analyst | Buy |
| Ask | 1.47 |
| Volume | 1,443,164 |
| Avg. Volume (20D) | 9,371,722 |
| Open | 1.48 |
| Previous Close | 1.49 |
| Day's Range | 1.43 - 1.54 |
| 52-Week Range | 0.22 - 1.97 |
| Beta | 1.00 |
About CGTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CGTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 days ago
+10.91%
Cognition Therapeutics shares are trading higher ...
Unlock content with
Pro Subscription
6 days ago
+28.1%
Cognition Therapeutics shares are trading higher after the company announced it received final minutes from the FDA pertaining to the end-of-Phase 2 meeting that confirmed the proposed design of the Phase 3 program may support a New Drug Application filing for zervimesine as a treatment for Alzheimer's disease.
